Futuristic hospital ward with patient receiving subcutaneous trastuzumab.

Trastuzumab Showdown: Is Subcutaneous the Future of Breast Cancer Treatment?

Theo Raines monogram
Theo Raines in Health & Wellness October 2026 • 4 min read.

"A Singapore study reveals the potential cost-saving benefits and efficiency improvements of subcutaneous trastuzumab administration for early and metastatic breast cancer."


Breast cancer remains a significant health concern for women worldwide. In Singapore, it accounts for 29% of all cancers affecting women. Advancements in treatment have dramatically improved survival rates and quality of life. Among these advancements, trastuzumab, a targeted therapy for HER2-positive breast cancer, has become a cornerstone of treatment.

Trastuzumab is prescribed for patients with HER2-positive early breast cancer (EBC) and metastatic breast cancer (MBC). Traditionally administered intravenously (IV), a subcutaneous (SC) formulation has emerged as a promising alternative. A new study from Singapore has explored the cost-saving potential of subcutaneous trastuzumab compared to intravenous administration.

This article will delve into the findings of the Singaporean cost-minimization analysis, examining the economic implications and efficiency improvements associated with subcutaneous trastuzumab. By understanding these benefits, healthcare providers and patients can make more informed decisions about treatment options, optimizing both outcomes and costs.

AI Search Multiple angles on this topic

Benefits and Risks of Trastuzumab

In early-stage, HER2-positive breast cancer, adding trastuzumab to chemotherapy reduces the risk of recurrence and death, but is associated with cardiac toxicity. One review investigated the long-term benefits and risks of adjuvant trastuzumab, including breast cancer recurrence and cause-specific mortality. A separate statistics page reports that trastuzumab plus chemotherapy improves five-year overall survival by 10 to 15 percent in HER2-positive breast cancer.

Established Treatment, Different Delivery Routes

Trastuzumab has been established as an efficacious and well-tolerated monotherapy in clinical trials, particularly in second- or third-line treatment settings. NICE guidance recommends monotherapy as an option for metastatic breast cancer with HER2 scored at 3 or more after at least two chemotherapy regimens; prior chemotherapy must have included an anthracycline and a taxane when appropriate. The PrefHer study's final analysis examined patient preferences for subcutaneous trastuzumab versus conventional intravenous infusion in adjuvant treatment of early HER2-positive breast cancer, drawing on 488 patients.

Subcutaneous Trastuzumab: A Cost-Effective Alternative?

Futuristic hospital ward with patient receiving subcutaneous trastuzumab.

The study, conducted by researchers in Singapore, compared the costs of subcutaneous versus intravenous trastuzumab for treating both early and metastatic breast cancer. The analysis considered drug costs and non-drug costs, such as pre-medications, drug preparation, venous access, trastuzumab administration, and facility expenses. Clinical inputs were gathered from field interviews, while cost data was obtained from public-sector hospital bills.

The study focused on comparing the expenses associated with SC versus IV trastuzumab over one course of EBC treatment and one course of MBC treatment. In particular it looked at 6 cycles of trastuzumab and chemotherapy, followed by 12 cycles of trastuzumab monotherapy for EBC. For MBC, the study assessed 8 cycles of trastuzumab and chemotherapy to a total of 26 cycles. The team used 58 kg as average patient weight.

  • Drug Cost Savings: SC trastuzumab significantly reduced drug costs compared to IV administration.
  • Non-Drug Cost Savings: Efficiency improvements with SC administration further lowered costs related to drug preparation, administration, and facility use.
  • Overall Cost Savings: Combining drug and non-drug cost reductions, SC trastuzumab resulted in substantial savings compared to IV administration.
AI Search Multiple angles on this topic

New Evidence and Risk-Adapted Treatment

A real-world multicenter study evaluated trastuzumab deruxtecan (T-DXd) in 64 patients with HR-negative, HER2-low metastatic breast cancer between May 2022 and May 2025. Another report describes T-DXd as an effective therapy for HER2-positive or HER2-low advanced breast cancer while highlighting interstitial lung disease as a particular toxicity. A recent Nature Reviews Clinical Oncology review describes a crowded HER2-positive treatment landscape and a shift toward risk-adapted approaches across early and metastatic disease.

Limits in Evidence and Cost Models

A global systematic review and meta-analysis rated the evidence for patient preference between subcutaneous and intravenous trastuzumab as low, citing substantial between-study heterogeneity (I² = 74%) and the subjective nature of preference. A Chilean cost-minimization analysis cautioned that its model assumed all patients underwent the same processes, which may differ from real clinical practice, and that its data came from a single institution. A separate meta-analysis of adverse effects noted serious risks of bias arising from heterogeneous outcome reporting and the open-label nature of the trials.

The results of the cost-minimization analysis revealed compelling findings. For the treatment of EBC and MBC over 26 cycles, subcutaneous trastuzumab resulted in a 13.1% total cost-savings compared to intravenous trastuzumab (S$62,811 vs. S$72,279). The 83% of total cost-savings were due to drug cost-savings with the rest made up by non-drug expenses (SC vs. IV: $60,362 vs. $68,242; SC vs. IV: $2,449 vs. $4,036, respectively).

Implications for Breast Cancer Treatment

The Singaporean study offers valuable insights into the economic benefits of subcutaneous trastuzumab. As healthcare systems strive to improve efficiency and reduce costs, the adoption of subcutaneous administration could represent a significant step forward. The reduced drug and non-drug costs associated with subcutaneous trastuzumab can free up resources for other essential healthcare services, ultimately benefiting patients and healthcare providers alike. Further research is needed to confirm these findings in diverse healthcare settings and to assess the long-term impact on patient outcomes.

AI Search Multiple angles on this topic

Nanomedicine and Antibody-Drug Conjugates

A review of trastuzumab-based nanomedicines describes trastuzumab as highly specific for its target antigen and reports that treatment has remained challenging and expensive to manage, with access barriers for underserved communities. It presents nanomedicine strategies and potential benefits for breast cancer drug research in low- and middle-income countries. A separate review reports successful results for trastuzumab-drug conjugates in HER2-expressing solid tumors and HER2-low breast cancers, suggesting they may have a future role in selected tumors with low HER2 expression or HER2 mutations.

Comparing Routes in Clinical Care

The phase 3, open-label, multicentre HannaH study randomly assigned patients with HER2-positive, operable, locally advanced, or inflammatory breast cancer to neoadjuvant chemotherapy with trastuzumab given every three weeks. Patients received either intravenous trastuzumab, with an 8 mg/kg loading dose and 6 mg/kg maintenance dose, or a fixed 600 mg subcutaneous dose. Separately, a real-world study was designed to assess treatment coverage and long-term outcomes, including prognostic parameters and recurrence patterns, among patients treated with adjuvant trastuzumab for early-stage HER2-positive breast cancer.

What route comparisons show about outcomes

The meta-analysis found no statistically significant difference in pathological complete response between the routes. This means its results did not establish that either route produced a higher rate of this outcome.[1]

Event-free survival results likewise showed no statistically significant difference between routes. That is not proof that the outcomes are identical; the cited result does not establish an advantage for either formulation.[1]

Efficiency gains and the limits of comparison

The evidence review notes that patient-oriented survival outcomes had not been proven for the subcutaneous formulation, and that the HannaH evidence concerned women with early breast cancer, while the proposed authorization also covered metastatic disease. This leaves the route comparison less settled for survival outcomes and metastatic disease than the treatment scope might imply.[2]

What further comparisons would need to clarify

  • Would the shorter chair and hospital times persist across different care settings and patient groups? The reported time comparisons establish a difference between routes, but not how consistently it applies beyond the measured comparison.[3]
  • Would outcome comparisons show meaningful differences in patient-oriented survival measures, particularly for metastatic disease? The cited evidence reports no statistically significant difference in pathological response or event-free survival, while noting limits in survival evidence and the early-disease scope of HannaH.[1] [2]

Sources

  1. Subcutaneous versus intravenous trastuzumab for HER2-positive breast cancer: a global systematic review and meta-analysis with a cost-minimization analysis from the Chinese healthcare system perspecti (pmc.ncbi.nlm.nih.gov)
  2. Evidence review | Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab | Advice | NICE (www.nice.org.uk)
  3. The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What is Trastuzumab, and why is it significant in the context of breast cancer treatment?

Trastuzumab is a targeted therapy specifically designed for patients with HER2-positive breast cancer. In the context of treatment, it has become a crucial part of therapy for both early breast cancer (EBC) and metastatic breast cancer (MBC). It's used to improve survival rates and enhance the quality of life for those with HER2-positive cancers. This is due to its ability to target and disrupt the growth of cancer cells that overexpress the HER2 protein, leading to a better prognosis for patients. This targeted approach is a significant advancement in cancer treatment.

2

What is the difference between subcutaneous and intravenous trastuzumab, and why does it matter?

Subcutaneous (SC) trastuzumab administration involves delivering the drug under the skin, in contrast to intravenous (IV) administration, which is given directly into a vein. The Singaporean study explores the cost-effectiveness of SC versus IV trastuzumab for early and metastatic breast cancer. The study demonstrates that SC administration is associated with a 13.1% total cost-savings over 26 cycles of treatment, mainly due to lower drug costs and reduced expenses in preparation, administration, and facility use. This means that SC trastuzumab can provide similar therapeutic benefits at a lower cost, potentially freeing up resources for other areas of healthcare.

3

How did the Singapore study compare subcutaneous and intravenous trastuzumab?

The Singaporean study compared the costs associated with both subcutaneous and intravenous trastuzumab for treating early breast cancer (EBC) and metastatic breast cancer (MBC). The researchers looked at the cost differences related to drug costs, the non-drug costs such as preparation, administration, and facility use. They compared the total expenses over one course of EBC treatment, which involved 6 cycles of trastuzumab and chemotherapy, followed by 12 cycles of trastuzumab monotherapy, and one course of MBC treatment involving 8 cycles of trastuzumab and chemotherapy to a total of 26 cycles. The study found that SC trastuzumab resulted in significant savings compared to IV administration, especially in drug costs. The analysis of 26 cycles highlighted a 13.1% total cost savings with SC.

4

What are the implications of the study's findings for breast cancer treatment?

The study's findings suggest that subcutaneous trastuzumab could lead to significant cost savings in breast cancer treatment. By reducing drug and non-drug costs, healthcare systems could free up resources to invest in other essential services, ultimately improving patient care. The economic benefits could also make treatment more accessible and affordable. Furthermore, the study indicates improved efficiency, reducing time and resources spent on drug preparation and administration. The implication is that moving toward SC trastuzumab could benefit both patients and healthcare providers, making cancer treatment more sustainable and effective. However, it's important to note the need for further research to validate these findings in various healthcare settings.

5

What was the main focus of the Singaporean study on trastuzumab?

The study focused on cost-minimization analysis. Researchers in Singapore examined the economic implications and efficiency improvements of subcutaneous trastuzumab compared to intravenous administration for treating both EBC and MBC. The main goal of this analysis was to find the most cost-effective way to administer trastuzumab while providing the same therapeutic benefits. The study considered drug costs and non-drug costs, such as pre-medications, drug preparation, venous access, trastuzumab administration, and facility expenses. By focusing on cost-minimization, the study provided valuable insights for healthcare providers and patients when making decisions on treatment options. It found that SC trastuzumab could reduce expenses without compromising treatment outcomes.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.